Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microsampling to facilitate therapeutic drug monitoring of oncolytics
NL-OMON57238Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib and 8 more in cancer (13 cohorts), sponsored by Leiden University Medical Center. Primary endpoint: Method agreement between whole blood sample and dried blood spot. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON57238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57238.